Bristol-Myers Squibb Company (BMY)
-NYSE | Prev Close: | 43.76 |
|---|
| Open: | N/A |
|---|
| Bid: | 43.99 x 300 |
|---|
| Ask: | 44.20 x 500 |
|---|
| 1y Target Est: | 39.30 |
|---|
| Beta: | 0.12 |
|---|
| Next Earnings Date: | 22-Jul-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 30.64 - 45.59 |
|---|
| Volume: | 975 |
|---|
| Avg Vol (3m): | 10,019,000 |
|---|
| Market Cap: | 71.88B |
|---|
| P/E (ttm): | 49.56 |
|---|
| EPS (ttm): | 0.88 |
|---|
| Div & Yield: | 1.40 (3.20%) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Pharmaceuticals companiesAP(Tue, 06:05 SGT)
- Midday Glance: Pharmaceuticals companiesAP(Tue, 01:17 SGT)
- Early Glance: Pharmaceuticals companiesAP(Mon, 20 May)
- FDA OKs Bristol's HIV drug for younger patientsAP(Sat, 4 May)
- Sanofi earnings slashed in first quarterAP(Thu, 2 May)
- Earnings Preview: Merck to key on coming new drugsAP(Tue, 30 Apr)
- Earnings Preview: Pfizer to report Q1 resultsAP(Sat, 27 Apr)
- Bristol net plunges 45 pct. on generic competitionAP(Thu, 25 Apr)
- Moody's sees pick-up in pharmaceutical industry M&A in 2013Reuters(Tue, 23 Apr)
- Merck, Bristol-Myers will test hepatitis C regimenAP(Mon, 22 Apr)
- Bristol-Myers Inks OTC DealZacks(Thu, 14 Feb)
- MDCO-BMY Deal Comes into EffectZacks(Tue, 12 Feb)
- Vical's Loss Narrower than ExpectedZacks(Sat, 9 Feb)
- Generics Continue to Hurt SanofiZacks(Sat, 9 Feb)
- Pipeline Setback for IdenixZacks(Fri, 8 Feb)
Key Statistics
| Forward P/E (1 yr): | 20.54 |
|---|
| P/S (ttm): | 4.44 |
|---|
| Ex-Dividend Date: | 03-Apr-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 1.81 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.44 |
|---|
| Mean Recommendation*: | 2.4 |
|---|
| PEG Ratio (5 yr expected): | 2.45 |
|---|
Business Summary
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide.
View More